Saxenda (Liraglutide 3 mg) Off-Label Use in Children Under 12: What the Evidence Actually Shows

What Is Saxenda and Why Does Age Matter?

Saxenda is liraglutide formulated at 3.0 mg/day for chronic weight management, distinct from the 1.2 mg and 1.8 mg doses of Victoza used for type 2 diabetes. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that reduces energy intake by acting on hypothalamic appetite centers and delaying gastric emptying. The FDA approved Saxenda for adults in December 2014 and extended that approval to adolescents aged 12 to 17 years in December 2020.

Age is a regulatory and physiological boundary, not just a number on a chart. Drug metabolism, receptor density, hormonal milieu, and growth trajectory all shift substantially between a 7-year-old and a 14-year-old. The FDA's age cutoff reflects where adequate, well-controlled trial data actually exist.

The Regulatory Line at Age 12

The December 2020 adolescent approval was based on the SCALE Teens trial, which enrolled participants aged 12 to 17. No equivalent randomized controlled trial has been conducted in children under 12 for the 3 mg formulation. Without that data package, the FDA cannot grant approval, and any prescribing below age 12 falls outside labeled indications.

This does not make off-label use illegal. Physicians may legally prescribe approved drugs for unapproved uses in the United States. The question is whether the evidence supports doing so safely and effectively in a patient under 12.

How Off-Label Prescribing Works in Pediatrics

Off-label prescribing is common across pediatric medicine. A 2014 analysis published in Pediatrics estimated that roughly 80% of drugs used in hospitalized children carry some off-label element. The mechanism is professional medical judgment, not a regulatory loophole. For weight-management drugs specifically, though, the bar is higher because the benefit-to-risk ratio in a growing child must account for long-term developmental effects that adult trials do not capture.

The SCALE Teens Trial: The Closest Available Evidence

The best available controlled data come from SCALE Teens (NCT02918279), a 56-week randomized, double-blind, placebo-controlled trial published in the New England Journal of Medicine in 2020. The trial enrolled 251 adolescents aged 12 to 17 with a BMI at or above the 95th percentile for age and sex and body weight exceeding 60 kg.

Primary Outcome and Weight Results

Participants receiving liraglutide 3 mg achieved a mean BMI standard deviation score (SDS) reduction of 0.22 compared with an increase of 0.15 in the placebo group, a difference of 0.37 SDS (P<0.001). In absolute BMI terms, the liraglutide group saw a mean reduction of roughly 2.8 kg/m², while placebo participants gained approximately 1.6 kg/m². About 43.3% of the liraglutide group achieved at least a 5% reduction in BMI versus 18.7% in the placebo group.

These results, while statistically significant, are more modest than those seen in adults. SCALE Obesity and Prediabetes (N=3,731) showed a mean weight loss of 8.4 kg in adults taking liraglutide 3 mg versus 2.8 kg with placebo at 56 weeks, as published in NEJM in 2015.

Safety Profile in the 12-to-17 Age Band

Gastrointestinal adverse events dominated. Nausea occurred in 43% of liraglutide-treated adolescents versus 17% with placebo. Vomiting was reported in 29% versus 9%. These rates are substantially higher than adult trial rates, where nausea affected roughly 39% of liraglutide recipients. The higher frequency in adolescents may reflect differences in GI motility regulation or titration speed.

Two liraglutide-treated participants experienced elevated lipase levels, and one reported pancreatitis-like symptoms that resolved after discontinuation. Suicidal ideation was not significantly elevated, but it was monitored as a protocol-specified event given FDA requirements for weight-management drugs.

No participants in SCALE Teens were under age 12. Extrapolating the 12-to-17 safety and efficacy data to a 9-year-old carries meaningful uncertainty.

Why Children Under 12 Represent a Distinct Clinical Population

Developmental Physiology

Children under 12 are in various stages of prepubertal or early pubertal development. Hypothalamic-pituitary-gonadal axis maturation, growth hormone pulsatility, and insulin sensitivity all change rapidly in this window. GLP-1 receptors exist in the hypothalamus, pancreas, and peripheral tissues, and receptor expression patterns in early childhood have not been systematically characterized in published human studies. The NIH's National Institute of Child Health and Human Development has noted that pharmacokinetic data in pre-adolescent children cannot reliably be inferred from adolescent or adult studies for most drug classes.

Bone mineral accrual peaks between ages 11 and 14 in girls and 13 and 17 in boys, according to data from the National Osteoporosis Foundation summarized by the NIH. A drug that suppresses appetite and caloric intake during this window could theoretically reduce calcium and vitamin D consumption at a time when skeletal development is highly sensitive. No long-term bone density data exist for liraglutide use starting before age 12.

The Obesity Burden in Under-12 Children

Childhood obesity is a genuine public health problem. CDC data show that approximately 19.7% of U.S. Children and adolescents aged 2 to 19 years had obesity between 2017 and 2020, with prevalence rising in younger age groups. Among children aged 6 to 11 years specifically, prevalence was approximately 19.6%. Severe obesity (BMI at or above 120% of the 95th percentile) affects roughly 6 to 7% of school-age children and carries real cardiovascular and metabolic risk even before adolescence.

The clinical need is not hypothetical. But need does not automatically justify a specific intervention when adequate safety data are absent.

Current Guideline Recommendations

The Endocrine Society's 2023 Clinical Practice Guideline on Pediatric Obesity recommends intensive lifestyle intervention as the primary treatment for children of all ages with obesity. For pharmacotherapy, the guideline states that weight-loss medications may be considered as adjunct treatment in adolescents aged 12 and older when lifestyle intervention alone is insufficient. For children under 12, the guideline does not recommend weight-loss pharmacotherapy as routine care and specifies that any such use requires careful individualized risk-benefit assessment.

The American Academy of Pediatrics 2023 Clinical Practice Guideline on Obesity, published in Pediatrics, similarly recommends against delaying evaluation and treatment for severe pediatric obesity, but it reserves pharmacotherapy recommendations for adolescents, with intensive behavioral therapy as the backbone of treatment for younger children.

What Off-Label Prescribing in Under-12 Children Might Look Like

A structured clinical decision framework for evaluating liraglutide 3 mg in a child under 12 with severe obesity might proceed through the following considerations. This framework is intended as a discussion tool for specialist review, not as a prescribing protocol.

Step 1: Confirm Failure of Guideline-Directed Lifestyle Therapy

No pharmacotherapy, approved or off-label, should be initiated without a documented period of intensive lifestyle intervention. The Endocrine Society and AAP guidelines both specify intensive health behavior and lifestyle treatment as a prerequisite. "Intensive" means at least 26 contact hours over 6 to 12 months with a multidisciplinary team, per the USPSTF 2017 recommendation on childhood obesity.

Step 2: Assess Comorbidity Severity

Children with BMI above 140% of the 95th percentile who carry serious comorbidities such as obstructive sleep apnea, non-alcoholic fatty liver disease, or pre-diabetes represent a population where the risk of withholding treatment may genuinely outweigh the risk of off-label pharmacotherapy. Even in this group, specialist referral to a pediatric obesity medicine program is the appropriate first step rather than primary-care prescribing.

Step 3: Rule Out Absolute Contraindications

Saxenda carries a black-box warning for medullary thyroid carcinoma (MTC). The drug is contraindicated in patients with a personal or family history of MTC or with multiple endocrine neoplasia type 2 (MEN2). This contraindication applies regardless of age. A thorough personal and family history for thyroid cancer and MEN2 is non-negotiable before any liraglutide prescription.

Additional contraindications include prior serious hypersensitivity reaction to liraglutide or any excipient, and active or prior pancreatitis. These must be evaluated in all patients, including children.

Step 4: Consider Alternative Approved Options

Before prescribing off-label liraglutide to a child under 12, it is worth noting that metformin has been used off-label in this population for insulin resistance and has a more extensive pediatric safety record. Orlistat is approved down to age 12. For children under 12 with extreme obesity and serious comorbidities, referral to a center with a bariatric surgery program for adolescents is appropriate, even if surgery is ultimately deferred until later.

Step 5: Informed Consent and Monitoring

If a specialist determines that liraglutide 3 mg is appropriate for an individual child under 12, written informed consent from parents or guardians and assent from the child (age-appropriate) should document the off-label nature of the prescription, the limited evidence base, and the monitoring plan. Monitoring should include height, weight, and BMI at every visit; gastrointestinal symptom review; amylase and lipase at baseline and periodically; thyroid function if symptoms suggest dysfunction; and growth velocity tracked against standard growth charts.

Dosing Considerations for Pediatric Off-Label Use

No validated dosing protocol exists for liraglutide 3 mg in children under 12. The adolescent SCALE Teens trial used the same titration schedule approved for adults:

• Weeks 1 to 2: 0.6 mg/day subcutaneous
• Weeks 3 to 4: 1.2 mg/day
• Weeks 5 to 6: 1.8 mg/day
• Weeks 7 to 8: 2.4 mg/day
• Week 9 onward: 3.0 mg/day (maintenance dose)

This titration was designed to minimize gastrointestinal side effects. In the 12-to-17 trial, even with this schedule, 43% of participants experienced nausea. A slower titration, stopping at a lower maintenance dose, has been used by some pediatric obesity specialists in off-label contexts, though no published trial data support a specific modified protocol in under-12 children.

Body weight-based dosing (mg/kg) is used for many pediatric medications, but liraglutide's dosing in all studied populations, including adolescents, has been fixed rather than weight-based. Whether a fixed adult dose is appropriate for a 30 kg child is genuinely unknown. The FDA Pediatric Advisory Committee has not issued guidance specific to this scenario.

Ongoing Research and What May Change the Picture

Several developments could shift the evidence base over the coming years.

The SCALE Kids trial (NCT04775082) is investigating liraglutide 3 mg in children aged 6 to 11 years with obesity. If completed and published with positive results, this trial could form the basis of an FDA sNDA filing for an extended age indication. Until that data exists in peer-reviewed form, the evidence gap remains real.

Semaglutide 2.4 mg (Wegovy) received FDA approval for adolescents aged 12 and older in December 2022 based on the STEP TEENS trial published in NEJM in 2022, in which semaglutide 2.4 mg produced a mean BMI reduction of 16.1% versus a 0.6% reduction with placebo over 68 weeks in 201 adolescents. Whether this more potent GLP-1 receptor agonist will generate evidence in under-12 children before liraglutide is unclear.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, is under investigation in adolescents but has no published pediatric trials at the time of this writing.

What Families and Clinicians Should Know

Families seeking treatment for a child under 12 with severe obesity are navigating a genuinely difficult situation. The science on pediatric obesity pharmacotherapy is moving faster than regulatory approvals can follow, but that gap does not mean evidence is available to guide safe off-label use in very young children.

A primary care physician who has never managed pediatric obesity pharmacotherapy should not be the one initiating off-label liraglutide in a 9-year-old. This belongs in a dedicated pediatric obesity medicine program or at minimum a pediatric endocrinology practice with access to a multidisciplinary team.

For families asking their pediatrician about Saxenda for a child under 12, the most accurate answer is this: the drug is not approved for this age group, no controlled trial has yet validated its use in children under 12, the side effect burden is substantial even in older adolescents, and a referral to a specialist center is the appropriate next step.

The Obesity Medicine Association maintains a directory of board-certified obesity medicine physicians, some of whom specialize in pediatric patients, and can be a useful resource for families who have not yet connected with specialist care.

Clinicians who do prescribe off-label liraglutide in under-12 children should document the clinical rationale thoroughly, obtain informed consent, follow a structured monitoring plan, and be prepared to discontinue if the child does not achieve at least a 4% BMI reduction at 16 weeks, which mirrors the stopping rule used in the approved adolescent indication per the Saxenda prescribing information.